In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Harry Crijns
Speaker
Harry Crijns
Harry Crijns Harry Crijns

Maastricht University Medical Centre (MUMC), Maastricht (Netherlands (The))

Specialities : Arrhythmias-General , Arrhythmias-General, Atrial Fibrillation, Pharmacology and Pharmacotherapy

Graduated in medicine at the University of Amsterdam in 1981, he completed his cardiology training at the University Medical Centre Groningen, The Netherlands in 1987, where he continued working as clinical cardiologist and electrophysiologist. He obtained a PhD at the University of Groningen in 1993 on 'Changes of Intracardiac Conduction Induced by Anti-arrhythmic Drugs - Importance of Use and Reverse Use-dependence'. He currently is Chair and professor of Cardiology, Maastricht University, board member of the Cardiovascular research Institute Maastricht (CARIM) and chairman of the Scientific Board of the Netherlands Heart Foundation. Contributions to the field include improved rate/rhythm control (RACE-trials, HATCH score), stroke prevention (CHA2DS2-VASc) and bleeding in AF (HAS-BLED). Current interests: idiopathic AF, atherothrombotic mechanisms in AF progression; hybrid AF ablation; early rhythm control in high risk AF.

19 presentations from this speaker

Gastro-intestinal disorders and arrhythmias

Event : EHRA 2019

  • Session : Arrhythmias in special clinical contexts
  • Speaker : H Crijns (Maastricht,NL)

One patient one substrate: time for individualised electrophysiology

Event : ESC Congress 2019

  • Session : The future of precision medicine: the case of cardiology
  • Speaker : H Crijns (Maastricht,NL), I Roca Luque (Barcelona,ES)

Randomised clinical trial of nurse-led integrated care for atrial fibrillation, a comparison with care as usual provided by the cardiologist

Event : ESC Congress 2019

  • Session : Late Breaking Science in Atrial Fibrillation 2
  • Speaker : P Wijtvliet (Roden,NL), H Crijns (Maastricht,NL)

Secondary atrial fibrillation - Does it recur?

Event : EHRA 2019

  • Session : Arrhythmias in special clinical contexts
  • Speaker : H Crijns (Maastricht,NL)

Wait-and-see versus acute cardioversion in recent-onset AF

Event : EHRA 2019

  • Session : Late-breaking trials 3
  • Speaker : H Crijns (Maastricht,NL)

How much must we investigate to diagnose lone atrial fibrillation?

Event : ESC Congress 2018

  • Session : "Lone Atrial Fibrillation": should the concept be abandoned?
  • Speaker : H Crijns (Maastricht,NL)
  • Joint with the Cardiac Society of Australia and New Zealand

Panel discussion.

Event : EHRA 2018

  • Session : Hybrid ablation - A role in atrial fibrillation management?
  • Speaker : H Crijns (Maastricht,NL), C Tondo (Milan,IT), L Boersma (Nieuwegein,NL), N Sood (Medford,US)
  • Sponsored by Radcliffe Cardiology

Pharmacological therapies in atrial fibrillation and HFpEF

Event : Heart Failure 2018

  • Session : Atrial fibrillation and HFpEF - Just twins?
  • Speaker : H Crijns (Maastricht,NL)

Two-way interactions between atrial fibrillation and coagulation

Event : EHRA 2018

  • Session : Atrial cardiomyopathy and fibrillation
  • Speaker : H Crijns (Maastricht,NL)

What is the value of a multidisciplinary atrial fibrillation heart team?

Event : EHRA 2018

  • Session : Hybrid ablation - A role in atrial fibrillation management?
  • Speaker : H Crijns (Maastricht,NL)
  • Sponsored by Radcliffe Cardiology

Impact of blood pressure control on avoiding or delaying atrial fibrillation

Event : ESC Congress 2017

  • Session : Preventing and delaying atrial fibrillation
  • Speaker : H Crijns (Maastricht,NL)

Future direction for research in atrial fibrillation.

Event : ESC Congress 2015

  • Session : Translational electrophysiology of atrial fibrillation
  • Speaker : H Crijns (Maastricht,NL)

Mechanisms of atrial fibrillation - potential targets for prevention of AF and practical tips.

Event : EHRA 2015

  • Session : Antiarrhythmic drugs for prevention of atrial fibrillation - what is new?
  • Speaker : H Crijns (Maastricht,NL)

CONFIRM-HF: Discussant review .

Event : ESC Congress 2014

  • Session : Hot Line: Cardiovascular disease: novel therapies
  • Speaker : H Crijns (Maastricht,NL)

RHYTHM-AF - What is current practise of cardioversion in Europe?

Event : ESC Congress 2014

  • Session : Cardioversion in Europe - New trends and treatments
  • Speaker : H Crijns (Maastricht,NL)
  • Sponsored by Cardiome International AG

Panel discussion and closing summary: novel oral anticoagulants for arterial and venous thrombosis.

Event : ESC Congress 2013

  • Session : Novel oral anticoagulants for arterial and venous thrombosis
  • Speaker : H Crijns (Maastricht,NL)
  • Sponsored by Boehringer Ingelheim

Panel discussion: novel oral anticoagulants for arterial and venous thrombosis.

Event : ESC Congress 2013

  • Session : Novel oral anticoagulants for arterial and venous thrombosis
  • Speaker : H Crijns (Maastricht,NL)
  • Sponsored by Boehringer Ingelheim

Prevention of progression towards persistent and permanent atrial fibrillation.

Event : ESC Congress 2013

  • Session : Ablation of paroxysmal atrial fibrillation: real impact over the long term?
  • Speaker : H Crijns (Maastricht,NL)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are